Nektar Therapeutics (NKTR)

42.81
1.10 2.70
NASDAQ : Health Technology
Prev Close 41.69
Open 42.10
Day Low/High 41.76 / 43.17
52 Wk Low/High 29.22 / 111.36
Volume 1.78M
Avg Volume 1.87M
Exchange NASDAQ
Shares Outstanding 173.09M
Market Cap 7.22B
EPS -0.60
P/E Ratio 10.09
Div & Yield N.A. (N.A)
Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Using My Metal Detector Amid Gold and Silver Strength

Using My Metal Detector Amid Gold and Silver Strength

Computer programming has found that buying bad-news dips is a consistent winner.

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Nektar Therapeutics (NKTR) Flagged As Strong On High Volume

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a strong on high relative volume candidate

Nektar Therapeutics (NKTR) Weak On High Volume Today

Nektar Therapeutics (NKTR) Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

Novice Trade: Nektar Therapeutics

Novice Trade: Nektar Therapeutics

Plus an update on the Urban Outfitters trade from yesterday.

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) Stock Slumps Despite Q4 Beat

Nektar Therapeutics (NKTR) stock is declining on Wednesday afternoon despite posting better-than-expected 2015 fourth quarter results after yesterday’s closing bell.

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

General Motors, MetLife and Tesla: Doug Kass' Views

General Motors, MetLife and Tesla: Doug Kass' Views

Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta's ADYNOVATE Meets Endpoints In Phase 3 Study Of Hemophilia A Patients Under 12 Years Of Age

Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase...

Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out

Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out

A rally to $19 could ensue for Nektar (NKTR) shares.

First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)

First Week of December 18th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new December 18th contracts and identified one put and one call contract of particular interest.

Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock

Nektar Therapeutics (NKTR) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

NKTR Makes Bullish Cross Above Critical Moving Average

NKTR Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of Nektar Therapeutics crossed above their 200 day moving average of $12.69, changing hands as high as $12.98 per share. Nektar Therapeutics shares are currently trading up about 1.6% on the day.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABTL, EFOI, IFT, JMBA, MRVC Downgrades: AAME, ASC, BCR, CCIH, CFX, CHS, CRAY, CRTN, EQT, EVRI, GE, GENC, MNK, MYE, NKTR, PFLT, PHH, RGS, SLG, STBZ, WABC, WAIR Initiations: BHBK, IMDZ, MTBC, NAME, NVCN, PFNX, TPUB, TSQ, XENT Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today

Nektar Therapeutics (NKTR) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

First Week of February 2016 Options Trading For Nektar Therapeutics (NKTR)

First Week of February 2016 Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options begin trading this week, for the February 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)

Today's Weak On High Volume Stock: Nektar Therapeutics (NKTR)

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Today's Perilous Reversal Stock: Nektar Therapeutics (NKTR)

Today's Perilous Reversal Stock: Nektar Therapeutics (NKTR)

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "perilous reversal" (up big yesterday but down big today) candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BZH, CAMT, CLR, DIN, EMN, HFBC, NKTR, POL, RDS.A, TMUS, WWWW Downgrades: ANH, BDC, CLD, CTCT, CWEI, GLRE, GOV, HBIO, LNG, MINI, MNR, NCR, ORN, PDLI, PEBO, TKR, VIA, VIAB Initiations: AAC Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock

Nektar Therapeutics (NKTR) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

First Week of NKTR June 19th Options Trading

First Week of NKTR June 19th Options Trading

Investors in Nektar Therapeutics saw new options begin trading this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new June 19th contracts and identified one put and one call contract of particular interest.

Interesting NKTR Put And Call Options For November 20th

Interesting NKTR Put And Call Options For November 20th

Investors in Nektar Therapeutics saw new options begin trading this week, for the November 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate

Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results

Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results

Nektar Therapeutics (NKTR) shares are down double digits after the company reported statistically insignificant phase III BEACON results for its breast cancer treatment candidate.

Nektar Therapeutics (NKTR): Heavy Pre-Market Activity

Nektar Therapeutics (NKTR): Heavy Pre-Market Activity

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a pre-market mover with heavy volume candidate

Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon

Fly Watch: Nektar Therapeutics Breast Cancer Data Expected Soon

The risk/reward ratio for shares of Nektar Therapeutics is "potentially interesting" heading into a data readout from a trial of its breast cancer treatment, JPMorgan stated.

First Week of March 20th Options Trading For Nektar Therapeutics (NKTR)

First Week of March 20th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 20th contracts and identified one put and one call contract of particular interest.

Interesting NKTR Put And Call Options For August 2015

Interesting NKTR Put And Call Options For August 2015

Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D+ (Sell)